Ikena Oncology, Inc. (NASDAQ:IKNA – Get Rating) – Equities research analysts at Jefferies Financial Group issued their Q1 2022 earnings estimates for shares of Ikena Oncology in a report released on Tuesday, April 12th. Jefferies Financial Group analyst K. Shi forecasts that the company will post earnings of ($0.39) per share for the quarter. Jefferies Financial Group also issued estimates for Ikena Oncology’s Q2 2022 earnings at ($0.41) EPS, Q3 2022 earnings at ($0.42) EPS, Q4 2022 earnings at ($0.39) EPS, FY2022 earnings at ($1.61) EPS, FY2023 earnings at ($1.64) EPS, FY2024 earnings at ($2.09) EPS, FY2025 earnings at ($2.91) EPS and FY2026 earnings at ($3.04) EPS.
Ikena Oncology (NASDAQ:IKNA – Get Rating) last released its quarterly earnings data on Thursday, March 17th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.57. The firm had revenue of $20.22 million for the quarter, compared to analyst estimates of $3.28 million.
NASDAQ IKNA opened at $6.99 on Friday. The firm has a 50 day moving average of $7.31 and a two-hundred day moving average of $11.02. Ikena Oncology has a 52 week low of $5.07 and a 52 week high of $26.49. The stock has a market capitalization of $251.01 million and a PE ratio of -2.18.
A number of hedge funds have recently bought and sold shares of the business. Legal & General Group Plc boosted its stake in shares of Ikena Oncology by 143.9% during the 4th quarter. Legal & General Group Plc now owns 2,273 shares of the company’s stock worth $29,000 after acquiring an additional 1,341 shares during the period. Morgan Stanley raised its holdings in shares of Ikena Oncology by 787.6% during the 3rd quarter. Morgan Stanley now owns 3,231 shares of the company’s stock worth $41,000 after buying an additional 2,867 shares in the last quarter. Baystate Wealth Management LLC bought a new stake in Ikena Oncology during the 4th quarter worth $38,000. Wells Fargo & Company MN bought a new stake in shares of Ikena Oncology in the 2nd quarter valued at about $59,000. Finally, Bank of America Corp DE bought a new position in shares of Ikena Oncology during the 2nd quarter worth approximately $60,000. Hedge funds and other institutional investors own 58.78% of the company’s stock.
About Ikena Oncology (Get Rating)
Ikena Oncology, Inc, a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.
- Get a free copy of the StockNews.com research report on Ikena Oncology (IKNA)
- Array Technologies Stock Giving Another Ground Floor Entry
- UiPath Stock is Nearing Rock Bottom Down Here
- 3 Undervalued S&P 500 Stocks to Buy Now
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.